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V I R O L O G Y
Genetic and structural insights into broad 
neutralization of hepatitis C virus by human  
VH1-69 antibodies
Netanel Tzarum1, Erick Giang2, Leopold Kong1, Linling He2, Jannick Prentoe3,  
Elias Augestad3, Yuanzi Hua1, Shaun Castillo2, Georg M. Lauer4, Jens Bukh3, Jiang Zhu1,2*,  
Ian A. Wilson1,5*, Mansun Law2*
An effective vaccine to the antigenically diverse hepatitis C virus (HCV) must target conserved immune epitopes. 
Here, we investigate cross-neutralization of HCV genotypes by broadly neutralizing antibodies (bNAbs) encoded 
by the relatively abundant human gene family VH1-69. We have deciphered the molecular requirements for 
cross-neutralization by this unique class of human antibodies from crystal structures of HCV E2 in complex with 
bNAbs. An unusually high binding affinity is found for germ line–reverted versions of VH1-69 precursor antibodies, 
and neutralization breadth is acquired during affinity maturation. Deep sequencing analysis of an HCV-immune 
B cell repertoire further demonstrates the importance of the VH1-69 gene family in the generation of HCV bNAbs. 
This study therefore provides critical insights into immune recognition of HCV with important implications for 
rational vaccine design.
INTRODUCTION
A prophylactic vaccine will be crucial for controlling the worldwide 
hepatitis C virus (HCV) epidemic. HCV infects an estimated 1 to 
2% of the world population, leading to 400,000 deaths annually (1), 
and is a major cause of liver failure and hepatocellular carcinoma. 
Recent advances have been made in the treatment of patients with 
persistent HCV infection using direct-acting antiviral (DAA) ther-
apies (2, 3). However, an effective HCV vaccine is still much needed 
because of the increase in new infections and the poor awareness of 
carriers, especially in developing countries and among marginalized 
populations (4, 5). Despite successful DAA treatment, patients with 
advanced liver disease remain at risk of liver cancer (6–8).
A major roadblock for HCV vaccine development is the genetic 
diversity of HCV, as demonstrated by 7 major HCV genotypes and 
more than 80 subtypes (9, 10). Therefore, an effective vaccine must 
induce robust immune responses against a wide spectrum of HCV 
variants. The E2 envelope glycoprotein mediates viral entry by bind-
ing the CD81 receptor and other host factors (11–13). The receptor 
binding site on E2 is likely surface exposed and structurally con-
served, thereby presenting a highly desirable target for broadly neu-
tralizing antibodies (bNAbs) known as the neutralizing face of E2. 
Similar to the HIV-1 envelope glycoprotein, HCV E2 is extensively 
covered by N-linked glycans (14) and has several variable regions 
(VRs), particularly hypervariable region 1 (HVR1), which shield 
conserved epitopes and assist in viral escape from NAbs (Fig. 1A) 
(9, 15).
Previously, we isolated a panel of human monoclonal Abs (mAbs) 
that recognize five distinct antigenic regions (ARs; AR1–5) on 
the HCV E1E2 glycoprotein complex (16, 17). While mAbs target-
ing AR1 and AR2 showed limited neutralizing activity, mAbs rec-
ognizing AR3 (AR3A–D) exhibit cross-genotype neutralization 
and inhibition of CD81 receptor binding to E1E2 (16, 17). The 
heavy chains (HCs) of AR3A–D share a similar genetic background 
and are derived from Ab precursors of the VH1-69 gene family that 
have been reported to be associated with cross-neutralization of 
HCV (16–19), influenza virus (20–24), and HIV-1 (25). Recently, 
two independent studies reported bNAbs isolated from pa-
tients that spontaneously cleared HCV and are also derived from 
VH1-69 genes and target AR3 (26, 27). These findings underscore 
the role of human VH1-69 Abs in combatting HCV infections and 
highlight the potential benefits of eliciting VH1-69–derived bNAbs 
by vaccination.
RESULTS
Here, we investigate how VH1-69 bNAbs achieve cross-genotype 
recognition of the E2 neutralizing face and the genetic requirements 
for the immune system to generate such bNAbs. To overcome the 
inherent flexibility of E2 (28), we designed an E2 core domain con-
struct (29) of the prototypic genotype 1a isolate, H77, and deter-
mined its crystal structure with bNAb AR3C (Fig. 1B and fig. S1A) 
(29). In parallel, Khan et al. (30) reported the crystal structure of a 
different E2 core construct derived from a genotype 2a isolate, J6, 
with nonneutralizing mAb 2A12. Structural analysis of H77 E2c 
in complex with AR3C Fab and alanine scanning mutagenesis 
(16, 29, 31) mapped AR3 to the E2 front layer and part of the CD81 
binding loop (amino acids 426 to 443 and 529 to 531; Fig. 1A and 
fig. S1). Most residues in AR3 are highly conserved among HCV 
genotypes (fig. S1C and table S1). Negative-stain electron micros-
copy revealed that in soluble E2, AR3 is exposed on the surface and 
not masked by the glycan shield or by VRs 1 to 3 (VR1–3; Fig. 1B) 
(29). To examine the accessibility of the AR3 neutralizing epitopes 
in soluble E2, we investigated binding of four AR3-directed mAbs 
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Fig. 1. Crystal structures of HK6a E2c3 and AR3 Fab complexes. (A) Schematic representations of the E2 core domain (amino acids 412 to 645) colored by structural 
components, with VRs in gray, front layer in cyan,  sandwich in red, CD81 loop in blue, and back layer in green. The E2 HVR1, stalk, and transmembrane region (amino 
acids 384 to 410 and 646 to 746) are not shown. The E2 N-linked glycans are indicated (29). (B) Modeling of the HVR1, VR2, and the Man6GlcNac2 N-linked glycans in the 
complex structure of H77 E2c, indicating the accessibility of AR3. The Man6GlcNac2 N-linked glycans were modeled on the basis of the N430 glycan in the H77 E2c struc-
ture [Protein Data Bank (PDB) entry 4MWF]. The AR3 is marked by a dashed line. The glycans that surround the AR3 are colored in dark gray. (C) KD values of various AR3 
immunoglobulin G (IgG) binding to E2TM, E2c, and E2c3 from genotypes 1a and 6a. (D) Neutralization breadth of AR3A–D, U1, and AR2A mAbs tested by HCVcc assays. 
Dendrograms shown for each mAb are colored on the basis of their half maximal inhibitory concentration (IC50) values. (E) Superposition of the crystal structures of HK6a 
E2c3-AR3A (blue), -AR3B (green), or -AR3D (pink) complexes with H77 E2c-AR3C (orange) illustrating the differences in the angle of approach of the AR3A–D mAbs to E2c. 
The structures of the HK6a E2c3-AR3A, -AR3B, or -AR3D complexes were superimposed with H77 E2c-AR3C on the basis of E2, and for each complex, the angle between 
the C atoms of HC V111, HC F54, and light chain (LC) I106 was calculated. The angle of approach was determined as the relative change in the angle between AR3A, 
AR3B, and AR3D mAbs to AR3C. For clarity, only the Fab VRs and the HK6a E2c3 structure are shown. (F) AR3 epitopes. The E2c structures are shown in surface represen-
tation, and the interacting residues in the epitopes were colored and labeled. (G) Schematic overview of the interactions between E2 and the AR3 HCs. The CDR sequences 
are aligned, and E2 interacting residues are highlighted in blue (hydrogen bonds) and green (hydrophobic interactions).
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AR3A–D to genotype 1a H77 E2 ectodomain (E2TM), E2c, and 
E2c3 [E2c with VR3 deleted (28)] (fig. S2A). Nanomolar binding 
(KD) for all three E2 constructs indicates that mAb recognition of 
AR3 is not dependent on the VRs (Fig. 1C and fig. S2B), whereas a 
notable reduction was observed in AR1A binding to E2c and E2c3 
(Fig. 1C and fig. S2B) (16). Modeling of Man6GlcNac2 N-linked gly-
cans onto the E2 glycosylation sites reveals that AR3 itself is devoid 
of glycans, although encircled by three glycans (N423, N430, and N532; 
Fig. 1, A and B, and fig. S1B). Removal of the E2c glycans by Endo-
glycosidase H (EndoH) treatment had negligible effect on bNAb 
binding, confirming that the glycans are not essential for high bind-
ing affinity of the AR3 mAbs and, in soluble E2, the AR3 epitopes 
are not shielded by glycans (Fig. 1C and fig. S2B). In contrast, AR1A 
binding was reduced by EndoH treatment, suggesting that the gly-
cans are essential for AR1A binding (Fig. 1C and fig. S2B).
Having established AR3 as a key site for HCV neutralization, 
we extended our structural efforts here to E2c constructs derived 
from other genotypes (see fig. S3A). The AR3A–D mAbs have cross- 
genotype binding activity (fig. S3B) that can be used to study the 
neutralizing face of E2. In addition, AR3A–C mAbs exhibited neu-
tralization breadth among genotypes 1 to 6 strains, whereas AR3D 
had a more restricted breadth in virus neutralization assays (Fig. 1D 
and fig. S3C). Crystallization trials of E2c from different genotypes 
with AR3A–D Fabs resulted in diffraction-quality crystals for E2c3 
of the HK6a isolate as complexes with AR3A, AR3B, and AR3D 
(table S2 and see also Materials and methods). The HK6a E1E2 glyco-
protein complex has been shown to be fully functional in vitro 
[HCV pseudotype particle (HCVpp) and cell culture HCV (HCVcc) 
systems] and in vivo (chimpanzee and human liver chimeric mouse 
models). The HK6a E2c3 structures (fig. S4A) revealed that the 
overall fold is similar to genotypes 1a H77 E2c (29) and 2a J6 E2 
core (30), with C root mean square deviations of 1.09 and 0.86 Å, 
respectively (for amino acids 491 to 645, using E2c3 from the AR3A 
complex as representative of the HK6a E2 structures). However, 
substantial conformational differences were observed in the  sand-
wich loop connecting 6 and 7 (amino acids 540 to 552; fig. S4B) 
in the VR3 region (fig. S4C) and in the N-terminal part of the back 
layer (amino acids 564 to 610). Less pronounced differences were 
seen in the C-terminal part of the back layer (amino acids 629 to 
640) and AR3C epitope of H77 E2 (AR3 is absent in the J6 structure; 
fig. S4B). The 6-7 loop of HK6a shows a different conformation 
compared to H77 and J6, which could result from an N540E substi-
tution that eliminates the seventh N-glycosylation site (N540) that 
is present in genotypes 1, 2, 4, and 5 but not in genotypes 3 and 6 
(figs. S3A and S4, D and E).
Superposition of four E2-AR3 Fab complexes indicates that 
these Abs bind AR3 with different angles of approach (Fig. 1E) and 
with their footprints mapped to different but overlapping parts of 
the antigenic surface (Fig. 1F), consistent with our previous bio-
physical study indicating flexibility of the E2 front layer and CD81 
binding loop (28) (fig. S4F). Analysis of the interactions between 
the AR3 Fabs and HK6a E2c3, compared to AR3C and H77 E2c 
(Fig. 1G and fig. S4G), indicates that E2 recognition is mediated 
mainly by their HCs (29) with few interactions with the LCs. The 
interaction between HC complementarity-determining regions 
(CDRs) 1 and 2 with AR3 mainly involves hydrophobic and aro-
matic side chains, whereas CDRH3 also makes a large number (5 to 
8) of main chain—main chain hydrogen bonds with E2 (Fig. 1G 
and table S3).
It has been shown that VH1-69–derived bNAbs against influenza 
virus and HIV-1 interact with conserved hydrophobic residues in 
their antigens via hydrophobic residues at the tip of their CDRH2 
loops (20–25). Sequence alignment of the VH1-69–encoded AR3 mAb 
HCs indicates a relatively low identity (62 to 73%) for the VH region 
(amino acids 1 to 110; fig. S5A) and even less for the CDR loops (35 
to 57%), especially CDRH3 (Fig. 1G). Nevertheless, the CDRH2 tip 
of AR3A–D mAbs still retains a hydrophobic motif of I/V52-P52a-
X53-F54 (X = hydrophobic residue; Fig. 2A), which makes hydro-
phobic contacts with a highly conserved hydrophobic pocket between 
the front layer and CD81 binding loop, despite some variations in 
CDRH2 interactions. The AR3 mAbs have longer than average 
CDRH3 loops (18 to 22 residues) that interact with a flexible region 
of the front layer (amino acids 430 to 437; Fig. 1G). Their CDRH3 
adopts a  hairpin stabilized by intra-CDR hydrogen bonds and fur-
ther enhanced by a disulfide between the CDRH3  strands in 
AR3A and AR3C (fig. S5B). The  hairpin conformations vary de-
pending on CDRH3 length, but the two glycines at its apex contact 
L427 and W529 (for AR3A–C) of E2 (fig. S5B). Buried surface area 
(BSA) analysis confirms the indispensable role of the HC (Fig. 2B 
and fig. S5C). The HC BSA is similar for AR3A, AR3C, and AR3D 
(648 to 683 Å2), but slightly greater for AR3B (797 Å2). Structural 
analysis suggests that the optimal CDRH3 length for the AR3-like 
bNAbs is 18 to 22 residues, because a shorter loop will likely gen-
erate steric clashes with E2, especially with glycans surrounding AR3 
(fig. S5D); a longer loop would result in E2 being further away 
(Fig. 2C), causing a reduction in binding and neutralization breadth, 
as observed for AR3D mAb (Fig. 1, C and D).
Therefore, we further characterized Abs from an HCV-immune 
Ab library (16, 17). Within 22 E1E2 HC binding groups, 7 were en-
coded by the VH1-69 germline (GL) gene with CDRH3 loops rang-
ing from 12 to 22 residues (fig. S5E). Abs from groups B (including 
AR1A) and E have shorter CDRH3s (15 or 12 residues, respectively) 
and little neutralization activity (16). Notably, CDRH2 of AR1A 
no longer contains the I/V52-P52a-X53-F54 hydrophobic motif 
(Fig. 2A). Fabs from group U also target AR3 (17), with a similar 
CDRH2 hydrophobic motif but a 17-residue CDRH3 (Fig. 2A and 
fig. S5F); mAb U1 however had limited neutralization breadth 
(Fig. 1D). A similar reduction was observed when CDRH3 of AR3A 
was shortened by 1 residue to 17 residues (fig. S5G). Together, the 
results suggest that a hydrophobic CDRH2 tip and CDRH3 length 
of 18 to 22 residues capable of forming main-chain hydrogen bonds 
with the E2 front layer are optimal for broad neutralization by AR3 
mAbs (Fig. 2D).
In the HIV field, it is widely acknowledged that maturation of 
bNAbs from their GL Ab precursors is a long evolutionary process 
(>2 to 5 years) involving selection for mutations contributing to B 
cell survival and improved Ab functions. Therefore, an in-depth 
analysis of how GL precursors recognize their target antigen can 
provide critical insights into bNAb induction (32). The IMGT 
V-QUEST program (33) was used to predict GL genes for HC (VH, 
DH, and JH) and LC (VL and JL) of AR3A–D mAbs (fig. S6A). The 
inferred GL precursors (AR3A–DGL) and variants with only the VH 
gene reverted (AR3A–D1–69) were synthesized. In comparison with 
anti-HIV bNAbs, AR3 mAbs exhibit relatively low levels of somatic 
hypermutation (SHM), with identity to the VH GL of 84 to 91% and 
74 to 84% at the nucleotide and amino acid levels, respectively 
(Fig. 3A and fig. S6B), similar to that of VH1-69 anti-influenza 
bNAbs (23). Although CDRH2 contains a number of mutations 
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(amino acid identity of 64 to 76% with GL), the CDRH2 hydro-
phobic motif that presumably initiates the interaction with the E2 
hydrophobic pocket is conserved from the GL (Fig. 3A). Binding of 
AR3GL and AR31–69 IgGs by enzyme-linked immunosorbent assay 
(ELISA) reveals that AR3A1–69, AR3B1–69, and AR3CGL interact 
with both H77 E2c and HK6a E2c (fig. S6C). Further quantification 
using biolayer interferometry for these GL precursors indicated 
only a 2- to 8-fold decrease in KD for H77 and 22- to 120-fold for 
HK6a (Fig. 3B and fig. S6D). AR3A–DGL and AR3A–D1–69 (34) 
exhibited some neutralization above the 50% level for AR3A1–69, 
AR3AGL, and AR3B1–69, and more weakly for AR3C1–69 and AR3CGL, 
mainly against genotypes 5a and 6a (Fig. 3C), suggesting that neutral-
ization breadth was acquired during affinity maturation. Thus, 
HCV binding and neutralization can be readily detected in VH1-69 
precursors.
Our GL reversion analysis and other studies (17, 18, 26) high-
light the important role of the VH1-69 gene family in E2 recognition 
and in broad neutralizing responses against HCV. Since the AR3 
mAbs were isolated from an HCV-immune phage display Ab library, 
we used next-generation sequencing (NGS) to characterize enrich-
ment of AR3-like mAbs during panning. The original and three other 
libraries from panning against native and epitope-masked E1E2 were 
subjected to NGS, followed by antibodyomics analysis (table S4 and 
see also Materials and methods). Quantitative library profiles show 
distinct patterns indicative of rapid enrichment after three panning 
steps (Pan1 to Pan3) using E1E2 (Fig. 4A). VH1 is predominantly 
Fig. 2. Features that enable broad neutralization by AR3 mAbs. (A) Alignment of the CDRH2 sequences of AR3 bNAbs and mAbs U1 and AR1A. The hydrophobic 
motif in CDRH2 is highlighted in red. (B) Surface area buried by the CDRs of AR3 mAbs on E2s. CDRH3 length is indicated in brackets. (C) Correlation between CDRH3 
length and LC surface area buried. CDRH3 is colored in red. (D) Interactions between E2 and CDRH1-3 of AR3A–D.
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selected in the converged Fab library, with VH1-69 accounting for 87% 
of the total VH population. A notable shift was observed in SHM, 
with the peak value increasing from 7–9% to 15–16% in Pan3 (Fig. 4A), 
and CDRH3 length also increased from 10 to 14 residues to enrich-
ment of 15 to 17 residues (Fig. 4A). Two- dimensional (2D) identity/
divergence plots visualize enrichment of AR1–3 mAbs from this Fab 
library (Fig. 4B and fig. S7A) by showing sequences with CDRH3 
identity of 85% or higher (orange dots with number and library per-
centage labeled). Using AR3C as an example, the 2D plot shows a 
slow but steady increase of AR3C-like HCs from 0.01% in the pre-
panning library to 0.5% in the third panning cycle. Similar trends 
were observed for other AR3 mAbs with long CDRH3s (fig. S7A). 
By comparison, AR1A shows rapid convergence during antigen se-
lection with a 14,500-fold increase (0.004 to 58%), consistent with the 
dominant peak of 15- residue CDRH3s (Fig. 4, A and B). In our analy-
sis, HCs with similar CDRH3 loops and low levels of SHM (0 to 10%) 
that represent intermediate Abs in the library were also identified 
(Fig. 4B, marked by rectangles, and fig. S7). This provides useful clues 
as to how these Abs evolved to acquire E1E2 specificity and affinity.
To assess the prevalence of VH1-69 AR3 mAbs in comparison to 
those targeting other E1E2 antigenic sites, we also sequenced the Fab 
libraries panned with an E1E2 antigen that was masked with AR1 
and AR3 Abs (17). HCV-specific mAbs of other GL origins were 
selected, including the VH1-18, VH3-30, and VH5-51 families, some 
of which are cross-NAbs that recognize AR4 and AR5 on the quater-
nary E1E2 complex. Other mAb groups include mAbs that bind to 
epitopes that overlap with AR4 and AR5 (mAbs from groups R1 
and S1) and non–cross-NAbs that bind to epitopes overlapping 
with AR1–3 [groups F, I, K, M, and T; for more details, see (17)]. 
Quantitative library profiles displayed little change in VH gene 
usage, SHM, and CDRH3 length during this epitope-masked panning 
(fig. S7B), confirming that mAbs AR4A and AR5A, although present 
in the prepanning library, were only slightly enriched during selection 
(fig. S7C). Thus, NGS analysis of an HCV-immune Fab library fol-
lowing antigen challenge revealed the prevalence of VH1-69–derived 
Abs targeting AR1 and AR3 of E2, whereas Abs of other GL origins 
recognize different E1E2 antigenic sites (Fig. 4C).
To investigate whether this VH1-69 preference is indeed common 
to HCV-specific bNAbs, we sequenced Ab repertoires of five pa-
tients with chronic HCV and compared their repertoires with those 
from  high levels of anti-E1E2 Ab titers and cross-neutralizing activity 
and compared their repertoires with those from five healthy individuals 
as controls. Overall, both repertoires displayed similar VH gene dis-
tributions, with three subjects in each group showing relatively high 
Fig. 3. The inferred GL of AR3 mAbs. (A) Alignment of the HC CDRs of AR3, AR3GL (inferred GL), and AR31–69 (reversion of only the VH gene to the VH1-69 sequence). The 
interacting residues in the mature mAbs are colored in blue (hydrogen bonds) and green (hydrophobic interactions). (B) Biolayer interferometry analysis of AR31–69 and 
AR3GL IgGs binding to H77 and HK6a E2c. (C) Single-dose (50 g/ml) neutralization assay of AR31–69 and AR3GL IgGs against the eight HCVcc JFH1-based Core-NS2 recom-
binants of genotypes 1 to 6. Error bars represent SEM.
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frequencies of VH1-69 (fig. S8A). The HCV-infected donor repertoires 
exhibit a slightly broader range of CDRH3 lengths than the uninfected 
controls [normal distribution peaking around 11 to 14 residues (Fig. 4D)], 
yet with no significant difference for the average length of the HCDR3 
loop between the two groups (fig. S10). Further analysis of the three 
largest VH gene families suggests that the distribution of some gene 
families could be affected by HCV infection (Fig. 4E). In contrast, 
both HCV-infected and healthy donors exhibit normal CDRH3 length 
distributions for the VH3-23 gene family. Some differences are also 
observed for other GL gene families (fig. S8B). Comparing the SHM 
between the two groups indicates similar distribution of both the HC 
and LC (fig. S8C). Comparison of the average SHM for the VH1-69 
gene family and for the overall VH repertoire indicates no significant 
difference between the two groups (fig. S10), although the sample 
size here is too small for conclusive statistical analysis.
DISCUSSION
The Centers for Disease Control and Prevention recently reported 
an almost threefold increase in the number of new HCV infections 
Fig. 4. Analysis of B cell repertoires of HCV-infected donors. (A) Quantitative B cell repertoire distribution of HC GL V gene usage, degree of SHM, and CDRH3 length 
and (B) identity/divergence analysis (to AR mAb/VH GL) of the prepanned and panned phage display Ab libraries. #a.a., number of amino acids. The panning experiments 
were performed using E1E2. (C) Schematic representation of the epitopes and the HC variable genes encoding the AR1–5 mAbs. The AR1–3 epitopes are shown on the 
E2 structure (16, 17, 31). bNAbs that target the AR3 epitopes are listed. (D) The distribution of CDRH3 length in the total HC GL V genes and (E) the three largest HC GL gene 
families of five patients with chronic HCV with high anti-E1E2 Ab titers and cross-neutralizing activity (top) and five healthy donors (bottom) as controls.
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in the United States between 2010 and 2015 (35), a result of the in-
crease in injection drug users caused by the opioid crisis in America 
(36), underscoring the urgent need for an effective HCV vaccine. 
The extreme genetic diversity of HCV demands elicitation of cross- 
genotype immune responses from vaccination. Therefore, structural 
understanding of bNAb recognition, together with the knowledge 
on how bNAbs develop from their GL precursors, is essential for the 
rational design of HCV vaccine immunogens (32, 37). As a main 
target for bNAbs, AR3 is highly conserved and overlaps with the 
majority of the E2 neutralizing face (29, 38). It was previously shown 
that, on native virions, HCV neutralization epitopes are shielded by 
HVR1 (9, 15) and glycans (39). To overcome the HCV escape by 
shielding of neutralization epitopes, it is crucial to design an antigen 
that can elicit a high level of bNAbs to conserved epitopes. Our results 
indicate that AR3 bNAb recognition of soluble E2 is largely inde-
pendent of VRs (HVR1, VR2, and VR3) or glycans, highlighting 
that the AR3 and the neutralizing face are promising targets for in-
clusion in an HCV vaccine, although a better understanding of the 
entire E1E2 complex would likely serve to optimize this further.
The E2c structures with bNAbs AR3A–D suggest that flexibility 
of the front layer facilitates binding of bNAbs encoded by the VH1-69 
GL gene family. Other critical features for breadth of AR3-like 
bNAbs include a hydrophobic CDRH2 tip and CDRH3 of around 
18 to 22 residues. The absence of one or more of these features can 
result in reduced neutralization breadth (as suggested for mAb U1; 
Fig. 1D). In contrast to HIV-1 (32), some AR3 inferred GL mAbs 
bind E2 with high affinity, and low to medium SHM is sufficient to 
neutralize virus, although further somatic mutation can improve 
breadth. Our results are consistent with a recent study (27), in which 
AR3-like bNAbs of VH1-69 origin and with similar SHM were iso-
lated from patients with spontaneous viral clearance, suggesting that 
HCV bNAbs can achieve broad neutralization with rapid lineage 
development. A possible reason is that the hydrophobic CDRH2 
motif that interacts with critical E2 residues for CD81 binding is GL 
encoded. The tip of the CDRH2 encoded by the VH1-69 gene is the 
most hydrophobic among the human HC genes (25) and there-
fore has superiority for targeting the hydrophobic E2 neutralizing 
face and hydrophobic pockets in the flu hemagglutinin stem region 
(22, 23). Since most of the interactions of CDRH3 with E2 are main 
chain—main chain hydrogen bonds, they can tolerate variation in 
the sequence of the CDRH3 and, therefore, low levels of SHM can 
be sufficient to optimize the interaction with E2.
While HCV-directed bNAbs can stem from different GL genes, 
bNAbs encoded by VH1-69 have been reported in multiple studies 
(16, 18, 26, 27), suggesting an important role of this Ab family in the 
immune response to HCV. Our analysis revealed that VH1-69 Abs 
target AR1 and AR3 on E2 when HCV E1E2 was the panning anti-
gen, but significant enrichment of AR1 non-NAbs suggests that 
AR1 may be more accessible in this format. However, other GL 
gene families are also involved in host Ab response to HCV. For 
rational vaccine design, a preferable strategy would appear to be de-
veloping HCV antigens that present the conserved AR3 neutraliz-
ing epitopes to engage the VH1-69 gene family, which is one of the 
frequent Ab families in the human Ab repertoire. It was recently 
reported that naïve B cells with high-avidity GL-encoded B cell re-
ceptors produce mainly IgM+ memory B cells following immuni-
zation in mice (40). If this is also true in humans, then one may 
expect that a GL-targeting strategy and E2-based vaccine antigens 
will trigger the generation of mostly antiviral VH1-69 IgM+ memory 
B cells. Such a strategy should be taken into consideration in HCV 
vaccine studies. Furthermore, HCV appears to be an excellent model 
for studying host humoral immunity to viral infection.
MATERIALS AND METHODS
Expression and purification of the soluble E2 from 
genotypes 1 to 6
The DNA constructs of the prototypic isolate H77 (41) for E2c 
(truncation of N and C termini and VR2 and removal of N448 and 
N576 glycosylation sites) and E2c3 (additional removal of VR3) 
were engineered on the basis of the soluble E2 ectodomain (E2TM, 
amino acids 384 to 717) as previously described (28, 29). On the 
basis of sequence similarity to H77, E2c constructs of HCV1 (42), 
CON1 (43), UKN1b12.6 (44), J6 (45), UKN3A1.28c (44), S52 (46), 
ED43 (47), SA13 (48), and HK6a (34) isolates and the E2c3 con-
structs of H77, ED43, and HK6a isolates were engineered and syn-
thesized by GeneArt (Invitrogen, USA; fig. S3A). Notably, the E1E2 
envelope glycoprotein complex of the HK6a isolate was previously 
shown to be fully functional in vitro using the HCVpp and HCVcc 
systems and in vivo in chimpanzee and human liver chimeric mouse 
models (34, 49, 50). The E2 constructs were expressed and purified 
as previously described (29).
Expression and purification of the AR3 IgGs and Fabs
IgGs AR1A, AR3A, AR3B, AR3C, AR3D, and U1 were expressed 
and purified as previously described (16). The AR3A–DGL and 
AR3A–D1–69 variable domain genes were synthesized by GeneArt 
(Invitrogen, USA), cloned into the pIgG vector, and expressed as 
previously described (16). Fabs AR3C and AR3D were cloned into 
the phagemid vector pComb3H and transformed into the BL21 
(DE3) bacterial strain (Novagen) for expression in the presence of 
IPTG (isopropyl--d-thiogalactopyranoside) overnight at 16°C. The 
bacterial cells were treated with lysozyme, sonicated, and the Fabs 
were purified on a protein G affinity column. Fabs AR3A and AR3B 
were generated from the corresponding IgGs (16) by papain diges-
tion (Sigma-Aldrich). All Fabs were further purified by size exclu-
sion chromatography using a Superdex 200 column (Pharmacia) in 
50 mM NaCl, 20 mM tris-HCl (pH 7.2) buffer.
Crystallization and structural determination of E2c3  
HK6a-Fab complexes
From the 10 HCV isolates, only 4 isolates [H77 (1a), J6 (2a), ED43 
(4a), and HK6a (6a)] gave high yield and were therefore used for the 
structural studies. The E2-Fab AR3 complexes were formed by 
overnight incubation of purified E2 and each AR3 Fab in a molar 
ratio of 1:1.25 (E2:Fab) at room temperature, followed by size exclu-
sion chromatography (Superdex 200) to remove unbound Fab 
using 20 mM tris and 50 mM NaCl (pH 7.2) buffer. Crystallization 
experiments were performed using the vapor diffusion sitting drop 
method at 20°C. Crystallization experiments of the E2c from the 
H77, J6, ED43, and HK6a isolates in complex with AR3A–D yield-
ed no crystals. However, further engineering the E2c proteins (E2c3; 
fig. S2A) resulted in crystals of the HK6a isolate in complexes with 
AR3A–D (table S2) that diffracted to 2.80, 2.60, and 3.30 Å for the 
AR3A, AR3B, and AR3D complexes, respectively, and to low res-
olution (~10 Å) for AR3C complexes. Crystals of the E2c3 HK6a-
Fab AR3A complex were obtained using a reservoir solution of 20% 
(w/v) PEG 3500, 0.2 M sodium citrate (pH 8.2); crystals of E2c3 
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HK6a-Fab AR3B complex from a reservoir solution of 20% (w/v) 
PEG 3500, 0.2 M Li chloride (pH 6.7); and crystals of E2c3 HK6a-
Fab AR3D complex from a reservoir solution of 20% (w/v) PEG 
6000, 0.1 M Hepes (pH 7.0). Prior to data collection, all crystals were 
cryoprotected with 10% ethylene glycol and flash cooled in liquid 
nitrogen. Diffraction datasets were collected at the Advanced Photon 
Source (APS) and the Stanford Synchrotron Radiation Lightsource 
(SSRL) (table S2). Data were integrated and scaled using HKL2000 
(51). The E2c3 HK6a-Fab AR3A structure was solved by molecular 
replacement method using Phaser (52), with the E2c H77-Fab 
AR3C (PDB entry 4MWF) as a search model. The E2c3 HK6a-Fab 
AR3B and E2c3 HK6a-Fab AR3D structures were solved by mo-
lecular replacement method using the refined E2c3 HK6a-Fab 
AR3A structure as a search model. Structure refinement was car-
ried out in Phenix (53), and model building was performed with 
COOT (54). Final refinement statistics are summarized in table S2.
Enzyme-linked immunosorbent assay
Purified E2 isolates were coated onto microwells at 5 g/ml over-
night at 4°C. After blocking with 4% (w/v) nonfat dry milk in dilu-
tion buffer (PBS + 0.02% Tween 20) for 30 min, titrated AR3 Abs 
(purified Ab for fig. S3B and transfected supernatant of Abs from 
293T cells for fig. S6C) in dilution buffer with 1% nonfat dry milk 
were added to the microwells and incubated for 1 hour at room tem-
perature. Titrated Abs were detected with secondary Ab horseradish 
peroxidase–conjugated goat anti-human IgG Fc (Jackson Immuno-
Research) and developed with 3,3′,5,5′-tetramethylbenzidine sub-
strate (Thermo Fisher Pierce). The reaction was stopped with 2 N 
sulfuric acid, and developed plates were read at absorbance of 
450 nm.
KD determination
KD values were determined by biolayer interferometry using an Oc-
tet RED instrument (ForteBio Inc.). IgGs at ~10 g/ml in a kinetics 
buffer [1× PBS (pH 7.4), 0.01% BSA, and 0.002% Tween 20] were 
immobilized onto protein G–coated biosensors and incubated with 
varying concentrations of E2 protein. The kon and koff values of each 
E2 protein for each IgG were measured in real time to determine KD 
values. All binding data were collected at 30°C.
Neutralization assay
In vitro neutralization was carried on Huh7.5 cells using either a 
single high dose (50 g/ml) or a dilution series of the relevant Ab as 
previously described (55). Control Ab b6 at the highest dose did not 
inhibit the viruses. For the dilution series experiments, IC50 values 
were calculated in GraphPad Prism 6 using a three-parameter curve 
fitting.
Panning of the phage display library
The construction of the phage display Ab library was previously 
described (16, 17). In summary, RNA of mononuclear cells from 
the bone marrow of a patient with chronic HCV was extracted, and 
complementary DNA (cDNA) was synthesized. LC and HC frag-
ments were amplified using gene-specific primers and cloned into 
phagemid vector with randomized HC and LC pairing. For antigen 
panning, the Ab Fab fragments were expressed as a fusion protein 
to the phage coat protein III for surface display. The HCV-immune 
phage display Ab library was panned for three consecutive rounds 
with increasing washing stringency in two different panning exper-
iments (16, 17). In the first experiment, recombinant E1E2 proteins 
captured by Galanthus nivalis lectin were used as the panning anti-
gens. In the second experiment, E1E2 antigens captured by mAb 
AR3A and blocked with mAb AR1B were used (17). In each pan-
ning step, antigen was directly coated onto a microtiter plate, fol-
lowed by blocking with 4% (w/v) milk in PBS. The phage library 
was added to the wells and incubated for 1 to 2 hours at 37°C, 
and unbound phages were washed away with PBS/0.5% (v/v) Tween 
20. Bound phages were eluted and used to infect freshly grown 
Escherichia coli (XL1-Blue, Stratagene) for titration on LB agar 
plates with carbenicillin.
Clinical samples
Normal blood donor samples were procured from the Normal 
Blood Donor Service (NBDS) of The Scripps Research Institute 
(TSRI). All healthy donors tested negative for hepatitis B virus, 
HCV, and HIV (56). Blood samples from patients with HCV with 
long-term chronic HCV viremia (genotype 1 or genotype 3) were 
collected at Massachusetts General Hospital. Informed consent was 
given by all subjects under a protocol approved by the Partners 
Human Research Committee [Institutional Review Board (IRB) 
no. 1999P004983]. Peripheral blood mononuclear cells (PBMCs) 
were extracted by Ficoll-Paque (GE Healthcare Life Sciences) den-
sity gradient centrifugation. Plasma samples were evaluated for 
E1E2-specific Ab by ELISA and for virus neutralizing activity using 
HCVpp (17). Five HCV+ donor samples with high cross-neutralizing 
activity and five random normal blood donor samples were selected 
for sequencing analysis below.
NGS and bioinformatics analysis
NGS was performed on the Ion Torrent Personal Genome Machine 
(PGM) and S5 systems. The HC regions of the Fab phage libraries 
were amplified from the plasmid stock using PCR with vector- 
specific primers (tables S4 and S5 and fig. S9). Notably, the forward 
primer contained a PGM/S5 full-length P1 adaptor, whereas the 
reverse primer contained a PGM/S5 A adaptor and an Ion Xpress 
barcode (Life Technologies) to differentiate Fab phage libraries. A 
total of 25 PCR cycles were performed, and the PCR products with 
an expected length of 500 to 600 bp were gel purified (Qiagen). The 
resulting HC libraries were quantitated using the Qubit 2.0 Fluorom-
eter with the Qubit dsDNA HS Assay Kit. The dilution factor 
required for PGM template preparation was determined such that 
the final concentration was 50 pM. For the prepanning Fab library 
(Pan0), template preparation was performed with the Ion PGM 
Template IA 500 Kit, followed by NGS on the Ion PGM system using 
the Ion PGM Hi-Q Sequencing Kit and an Ion 316 v2 chip. For the 
postpanning libraries (Pan1 to Pan3) obtained from two E1E2 pan-
ning procedures, template preparation and (Ion 530) chip loading 
were performed on Ion Chef using the Ion 530 Ext Kit, followed by 
NGS on the Ion S5 System. For five normal donors and five 
HCV-infected donors studied here, a previously reported 5′-RACE 
(rapid amplification of cDNA ends)  PCR protocol was used to cap-
ture their B cell repertoires in an unbiased manner (table S4) (57). 
Briefly, total RNA was extracted from 5 to 10 million PBMCs into 
30 l of water with the RNeasy Mini Kit (Qiagen). 5′-RACE was 
performed with the SMARTer RACE cDNA Amplification Kit 
(Clontech). The Ig PCRs were set up with the Platinum Taq High- 
Fidelity DNA Polymerase (Life Technologies) in a total volume of 
50 l, with 5 l of cDNA as template, 1 l of 5′-RACE primer, and 1 l 
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of 10 M reverse primer. The 5′-RACE primer contained a PGM/S5 P1 
adaptor, whereas the reverse primer contained a PGM/S5 A adaptor and 
an Ion Xpress barcode (Life Technologies) to differentiate donor librar-
ies. A similar PCR protocol (25 cycles) was used, and the PCR products 
with an expected length of 600 bp were gel purified (Qiagen). The Ab HC 
and LC ( and ) libraries were quantitated using the Qubit 2.0 Fluorom-
eter with the Qubit dsDNA HS Assay Kit and mixed at a ratio of 1:1:1 
for each donor. The five donor libraries were further mixed at an equal 
ratio for template preparation and (Ion 530) chip loading on Ion Chef 
using the Ion 530 Ext Kit. NGS was performed on the Ion S5 System 
with default settings. The human antibodyomics pipeline (57–63) 
was used to process and annotate the NGS data of Fab libraries and 
Ab repertoires. Notably, a number of methodological modifications 
have been made to the pipeline to improve data quality (64).
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